Marshall Wace, LLP Xenon Pharmaceuticals Inc. Transaction History

Marshall Wace, LLP

$90.8 Billion
Q3 2025

A detailed history of Marshall Wace, LLP transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 611,982 shares of XENE stock, worth $24.9 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

611,982

Previous 1,020,254 40.02%

Holding current value

$24.9 Million

Previous $31.9 Million 23.05%

% of portfolio

0.03%

Previous 0.04%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$30.3 - $40.15 $12.4 Million - $16.4 Million	-408,272 Reduced 40.02%	611,982 $24.6 Million
Q2 2025 Aug 13, 2025	BUY	$28.23 - $38.37 $7.4 Million - $10.1 Million	262,109 Added 34.57%	1,020,254 $31.9 Million
Q1 2025 May 15, 2025	SELL	$33.55 - $40.74 $4.75 Million - $5.77 Million	-141,573 Reduced 15.74%	758,145 $25.4 Million
Q4 2024 Feb 13, 2025	SELL	$38.14 - $45.74 $11.3 Million - $13.5 Million	-295,762 Reduced 24.74%	899,718 $35.3 Million
Q3 2024 Nov 14, 2024	SELL	$36.12 - $43.96 $6.83 Million - $8.32 Million	-189,194 Reduced 13.66%	1,195,480 $47 Million

Q2 2024 Aug 14, 2024	SELL	$36.25 - $43.75 $2.38 Million - $2.87 Million	-65,668 Reduced 4.53%	1,384,674 $54 Million
Q1 2024 May 15, 2024	SELL	$42.66 - $50.04 $3.34 Million - $3.92 Million	-78,306 Reduced 5.12%	1,450,342 $62.4 Million
Q4 2023 Feb 14, 2024	SELL	$28.7 - $46.46 $18 Million - $29.1 Million	-625,746 Reduced 29.05%	1,528,648 $70.4 Million
Q3 2023 Nov 14, 2023	SELL	$34.16 - $39.73 $5.67 Million - $6.6 Million	-166,025 Reduced 7.15%	2,154,394 $73.6 Million
Q2 2023 Aug 14, 2023	SELL	$34.84 - $43.54 $5,818 - $7,271	-167 Reduced 0.01%	2,320,419 $89.3 Million
Q1 2023 May 15, 2023	SELL	$33.46 - $40.35 $1.53 Million - $1.84 Million	-45,592 Reduced 1.93%	2,320,586 $83.1 Million
Q4 2022 Feb 14, 2023	SELL	$33.06 - $39.43 $14.7 Million - $17.5 Million	-444,917 Reduced 15.83%	2,366,178 $93.3 Million
Q3 2022 Nov 14, 2022	BUY	$30.79 - $39.82 $25.3 Million - $32.7 Million	820,723 Added 41.23%	2,811,095 $101 Million
Q2 2022 Aug 15, 2022	BUY	$25.44 - $35.16 $11.6 Million - $16 Million	456,314 Added 29.75%	1,990,372 $60.5 Million
Q1 2022 May 16, 2022	BUY	$25.09 - $33.13 $7.86 Million - $10.4 Million	313,101 Added 25.64%	1,534,058 $46.9 Million
Q4 2021 Feb 14, 2022	BUY	$15.6 - $35.4 $18.6 Million - $42.2 Million	1,191,154 Added 3996.76%	1,220,957 $38.1 Million
Q3 2021 Nov 15, 2021	BUY	$14.86 - $19.45 $287,541 - $376,357	19,350 Added 185.11%	29,803 $456,000
Q2 2021 Aug 13, 2021	BUY	$16.81 - $20.0 $175,714 - $209,060	10,453 New	10,453 $195,000
Q4 2020 Feb 16, 2021	SELL	$9.49 - $16.04 $354,404 - $599,013	-37,345 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$10.82 - $13.35 $493,034 - $608,319	-45,567 Reduced 54.96%	37,345 $413,000
Q2 2020 Aug 13, 2020	BUY	$10.21 - $14.9 $846,531 - $1.24 Million	82,912 New	82,912 $1.04 Million
Q1 2020 May 15, 2020	SELL	$8.08 - $17.57 $392,736 - $854,007	-48,606 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$8.11 - $14.65 $394,194 - $712,077	48,606 New	48,606 $637,000

Others Institutions Holding XENE

# of Institutions

239

Shares Held

73.9M

Call Options Held

235K

Put Options Held

271K

View Full List

About Xenon Pharmaceuticals Inc.

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.54B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

More about XENE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Xenon Pharmaceuticals Inc. Transaction History